Effectiveness of Education, Medication Adjustment and Telemonitoring in Reducing Diabetes Complications During Ramadan
NCT06033872 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79
Last updated 2023-12-08
Summary
Introduction Diabetes is a global emergency with detrimental clinical and financial consequences. Poorly managed diabetes leads to a myriad of serious complications, especially cardiovascular and infectious complications, with consequent increased cost and mortality rate. For Muslims in particular, the annual fasting month of Ramadan is one such period when diabetes control is essential. Adequate adjustments in diabetes management need to be made in line with the allowed meal times to avoid the risk of diabetes complications during Ramadan.
Objective Investigators aim to investigate the effectiveness of focused diabetes education and medication adjustment with telemonitoring to reduce diabetes complications during Ramadan fasting as well as to assess the cost-effectiveness of this intervention for Muslims with diabetes in Singapore.
Methodology In a parallel group randomized controlled trial, investigators aim to recruit 100 adults with diabetes who are able to fast at least 15 days in Ramadan. Participants will be randomized to the intervention group comprising of focused diabetes education, medication adjustment and telemonitoring, and control group receiving standard care. Participants will be followed up during Ramadan. The primary outcome is the incidence of hypoglycemia in Ramadan. The secondary outcomes are (i) incidence of other diabetes complications in Ramadan episodes including hyperglycemia, episodes of acute infections, attendances in clinic and emergency department and that of hospital admission, and (ii) cost-effectiveness of the intervention.
Clinical Significance The study enables investigators to evaluate focused pre-Ramadan diabetes education and medication adjustment with tele-monitoring as a means to reduce the markedly increased risk of diabetes complications for a large population during the fasting month, with potential for increased cost-effectiveness through reducing unscheduled attendances at clinic and hospital.
Conditions
- Diabetes Mellitus
- Fasting
- Diabetes Complications
Interventions
- COMBINATION_PRODUCT
-
Focused education, medication adjustment and telemonitoring
1. Focused diabetes education session for Ramadan fasting Participants will be taught to record 1. Meal plans 2. Physical activities 3. Blood glucose monitoring, and 4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia. 2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting. 3. Telemonitoring Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software.
Sponsors & Collaborators
-
SingHealth Polyclinics
collaborator OTHER -
Singapore Clinical Research Institute
collaborator OTHER -
Sengkang General Hospital
lead OTHER
Principal Investigators
-
Sueziani B Zainudin, MBBS FRCPG · Sengkang General Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-25
- Primary Completion
- 2021-09-01
- Completion
- 2022-05-31
Countries
- Singapore
Study Locations
More Related Trials
-
Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin
NCT01341717 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
NCT04365517 ·Status: UNKNOWN ·Phase: PHASE3
-
Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan
NCT00766441 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
NCT01131182 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
NCT01488279 ·Status: COMPLETED ·Phase: NA
-
Sitagliptin and Glucagon Counterregulation
NCT02256189 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes
NCT02307695 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Sitagliptin in Impaired Glucose Tolerance
NCT00961363 ·Status: UNKNOWN ·Phase: PHASE2
-
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
NCT06080802 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
NCT02917031 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.
NCT06719661 ·Status: COMPLETED ·Phase: NA
-
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00383877 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
NCT01340768 ·Status: COMPLETED ·Phase: PHASE3
-
Optimizing Care of Patients Via Telehealth In Monitoring and Augmenting Their Control of Diabetes Mellitus
NCT04306770 ·Status: UNKNOWN ·Phase: NA
-
Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
NCT00699322 ·Status: UNKNOWN ·Phase: PHASE4
-
DPP-4 Inhibition, Incretins and Islet Function
NCT02089438 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus
NCT01545024 ·Status: UNKNOWN
-
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
NCT05103306 ·Status: UNKNOWN
-
Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.
NCT07019012 ·Status: RECRUITING ·Phase: PHASE4
-
Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes
NCT02987738 ·Status: COMPLETED ·Phase: PHASE1
-
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
NCT03233178 ·Status: COMPLETED
-
Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy
NCT03700801 ·Status: COMPLETED ·Phase: PHASE4
-
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
NCT03659461 ·Status: COMPLETED ·Phase: NA
-
Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor
NCT03178591 ·Status: COMPLETED ·Phase: PHASE4
-
Human Solute Carrier Family 5 Member 2 (SLC5A2) Deficiency and the Glucagon-Incretin Axis
NCT03965000 ·Status: UNKNOWN